Upregulation of topoisomerase IIα expression in advanced gallbladder carcinoma: A potential chemotherapeutic target

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 7, 2008, Pages 793-801

  Washiro, Mitsutsune ^a   Ohtsuka, Masayuki ^a   Kimura, Fumio ^a   Shimizu, Hiroaki ^a   Yoshidome, Hiroyuki ^a   Sugimoto, Takashi ^b   Seki, Naohiko ^a   Miyazaki, Masaru ^a  

^a CHIBA UNIVERSITY   (Japan)

^b HITACHI LTD   (Japan)

Author keywords

Chemotherapy; Gallbladder carcinoma; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IDARUBICIN; TOPOISOMERASE 2ALPHA; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; DRUG DERIVATIVE; MESSENGER RNA; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; DRUG POTENCY; DRUG TARGETING; FEMALE; GALLBLADDER CARCINOMA; GALLBLADDER EPITHELIUM; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCREENING; TARGET CELL; UPREGULATION; VALIDATION PROCESS; BIOSYNTHESIS; CARCINOMA; CELL PROLIFERATION; DRUG EFFECT; GALLBLADDER TUMOR; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA; CELL PROLIFERATION; DEOXYCYTIDINE; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOXORUBICIN; ETOPOSIDE; FEMALE; GALLBLADDER NEOPLASMS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IDARUBICIN; IMMUNOHISTOCHEMISTRY; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 43449084088     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0348-0     Document Type: Article

References (34)

1. Ajiki T, Onoyama H, Yamamoto M, Asaka K, Fujimori T, Maeda S, Saitoh Y (1996) p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology 43:521-526
2. Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK (2005) Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma. A north central cancer treatment group phase II trial. Cancer 103:111-118
3. Chiu CC, Lin CH, Fang K (2005) Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis. Apoptosis 10:643-650
4. Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim JS, Kim YH (2000) Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 23:425-428
5. Clifford B, Beljin M, Stark GR, Taylor WR (2003) G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res 63:4074-4081
6. Davies SM, Robson CN, Davies SL, Hickson ID (1988) Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 263:17724-17729
7. de Rocha AO, Coutinho LM, Scholl JG, Leboutte LD (2004) The value of p53 protein expression in gallbladder carcinoma: analysis of 60 cases. Hepatogastroenterology 51:1310-1314
8. Dingemans AMC, Witlox A, Stallaert RALM, van der Valk P, Postmus PE, Giaccone G (1999) Expression of DNA topoisomerase IIα and topoisomerase IIβ gene predict survival and response to chemotherapy in patients with small lung cancer. Clin Cancer Res 5:2048-2058
9. Dingle BH, Rumble RB, Brouwers M, Cancer care Ontario's program in evidenced-based care's gastrointestinal cancer disease site group (2005) The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can J Gastroenterol 19:711-716
10. Donohue JH (2001) Present status of the diagnosis and treatment of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 8:530-534
11. Egan EA, Solomon MJ (1998) Cyclin-stimulated binding of Cks proteins to cyclin-dependent kinases. Moll Cell Biol 18:3659-3667
12. Evan GI, Brown L, Whyte M, Harrington E (1995) Apoptosis and the cell cycle. Curr Opin Cell Biol 7:825-834
13. Guinee DG, Holden JA, Benfield JR, Woodward ML, Przygodzki RM, Fishback NF, Koss MN, Travis WD (1996) Comparison of DNA topoisomerase IIα expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chmotherapeutic response. Cancer 78:729-735
14. Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL (2002) The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 277:16547-16552
15. Karpinich NO, Tafani M, Schneider T, Russo MA, Farber JL (2006) The course of etoposide-induced apoptosis on Jurkat cells lacking p53 and Bax. J Cell Physiol 208:55-63
16. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph (2002) Culprit and victim-DNA topoisomerase II. Lancet Oncol 3:235-243
17. Kimura K, Saijo M, Ui M, Enomoto T (1994) Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J Biol Chem 269:1173-1176
18. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332-2338
19. Lew DJ, Kornbluth S (1996) Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol 8:795-804
20. Lin MH, Chen JS, Chen HH, Su WC (2003) A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 49:154-158
21. MacGrogan G, Rudolph P, de Mascarel I, Mauriac L, Durand M, Avril A, Dihuydy JM, Robert J, Mathoulin-Pelissier S, Picot V, Floquet A, Sierankowski G, Coindre JM (2003) DNA topoisomerase IIα expression and response toprimary chemotherapy in breast cancer. Br J Cancer 89:666-671
22. Malik IA, Aziz Z (2003) Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder. Am J Clin Oncol 26:124-126
23. Misra S, Chaturvedi A, Misra NC, Sharma ID (2003) Carcinoma of the gallbladder. Lancet Oncol 4:167-176
24. Miyazaki M, Ito H, Ambiru S, Shimizu H, Togawa A, Gohchi E, Nakajima N, Suwa T (1996) Radical surgery for advanced gallbladder carcinoma. Br J Surg 83:478-481
25. Murad AM, Guimaraes RC, Aragao BC, Rodrigues VH, Scalabrini-Neto AO, Padua CA, Moore FC (2003) Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. Am J Clin Oncol 26:151-154
26. Nakopoulou L, Zervas A, Lazaris AC, Constrantinides C, Stravodimos C, Davaris P, Dimopoulos C (2001) Predictive value of topoisomerase IIα immunostaining in urothelial bladder carcinoma. J Clin Pathol 54:309-313
27. Nitiss JL, Liu YX, Harbury P, Jannatipour M, Wasserman R, Wang JC (1992) Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 52:4467-4472
28. O'Connor JK, Hazard LJ, Avent JM, Lee RJ, Fischbach J, Gaffney DK (2006) Topoisomerase IIα expression correlates with diminished disease-free survival in invasive breast cancer. Int J Radiat Oncol Biol Phys 65:1411-1415
29. Saxman SB, Finch D, Gonin R, Einhorn LH (1998) Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 16:702-706
30. Sobin LH, Wittekind Ch (eds) (2002) International union against cancer: TNM classification of malignant tumors. 6th edn. Wiley-Liss, New York
31. Taieb J, Mitry E, boige V, Artru P, Ezenfis J, Lecomte T, Clavero-Fabri MC, Vaillant JN, Rougier P, Ducreux M (2002) Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 13:1192-1196
32. Townsley FM, Aristarkhov A, Beck S, Hershko A, Ruderman JV (1997) Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci USA 94:2362-2367
33. Wu GS, Ding Z (2002) Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 21:1-8
34. Yin D, Tamaki N, Kokunai T (2000) Wild-type p53-dependent etoposide-induced apoptosis mediated by caspase-3 activation in human glioma cells. J Neurosurg 93:289-297